Dissecting intensive treatment as risk factor for inhibitor development in haemophilia

Haemophilia. 2016 May;22(3):e241-4. doi: 10.1111/hae.12944. Epub 2016 Apr 14.

Authors

C L Eckhardt¹, A S van Velzen¹, C J Fijnvandraat¹, J G van der Bom²

Affiliations

¹ Department of Pediatric hematology, Emma Children's hospital, Academic Medical Center, Amsterdam, the Netherlands.
² Jon J. van Rood Center for Clinical Transfusion Research, Sanquin Research and Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.

PMID: 27076357
DOI: 10.1111/hae.12944

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / blood*
Clinical Trials as Topic
Factor VIII / immunology
Factor VIII / therapeutic use*
Hemophilia A / drug therapy*
Hemophilia A / pathology
Hemophilia A / surgery
Humans
Risk Factors
Severity of Illness Index

Substances

Antibodies, Neutralizing
Factor VIII